Scholarlink

<p>Precision oncology is increasingly moving beyond genomics alone to approaches that directly test how patient tumors respond to therapy. This shift reflects a central challenge in oncology, where sequencing alone often fails to identify effective therapies for rare, treatment-resistant, or genomically ambiguous tumors. Here, we highlight three-dimensional (3D) microtumor models as a powerful functional platform that preserves the architecture, cell types, and microenvironment of intact tumors for drug screening. By capturing biology that 2D models and genomics alone miss, this approach enables more accurate prediction of therapeutic vulnerabilities and expands the precision-oncology toolkit for patients who currently lack actionable options.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Beyond genomics: 3D microtumor assays for rapid, clinically relevant functional drug testing

  • 期刊论文

  • 发表日期：

    2025年11月25日

查看全文
  • Marina Chan,
  • Taranjit S. Gujral

摘要

Precision oncology is increasingly moving beyond genomics alone to approaches that directly test how patient tumors respond to therapy. This shift reflects a central challenge in oncology, where sequencing alone often fails to identify effective therapies for rare, treatment-resistant, or genomically ambiguous tumors. Here, we highlight three-dimensional (3D) microtumor models as a powerful functional platform that preserves the architecture, cell types, and microenvironment of intact tumors for drug screening. By capturing biology that 2D models and genomics alone miss, this approach enables more accurate prediction of therapeutic vulnerabilities and expands the precision-oncology toolkit for patients who currently lack actionable options.